What question did this study set out to answer?

The study aims to evaluate the efficacy of Guselkumab in reducing extraintestinal manifestations (EIMs) in individuals with moderately to severely active Crohn's Disease.

January 23, 2026Journal of Crohn s and Colitis

DOP001Extraintestinal manifestations in participants with moderately to severely active Crohn’s disease: Results from the phase 3 GALAXI 2 & 3 studies

View Full Paper

Ask AI

Bookmark

The study aims to evaluate the efficacy of Guselkumab in reducing extraintestinal manifestations (EIMs) in individuals with moderately to severely active Crohn's Disease.
Participants were randomly assigned to receive Guselkumab or placebo.
EIMs were tracked at various time points including baseline and week 12 after treatment initiation.
Corticosteroid use was maintained and tapered according to protocol.
Overall EIM prevalence at baseline was 34.5% for Guselkumab and 42.6% for placebo.
At week 12, a higher proportion of Guselkumab recipients experienced resolution of their EIMs compared to placebo.
Guselkumab showed significantly improved scores on the Crohn’s Disease Activity Index component related to EIMs compared to placebo.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Phase 3 trials show Guselkumab improves EIMs in individuals with active Crohn's Disease, suggesting potential benefits.

Cite This Study

Danese et al. (2026) studied this question.

synapsesocial.com/papers/69730f78c8125b09b0d1f3e4 https://doi.org/10.1093/ecco-jcc/jjaf231.038

View Full Paper

Ask AI

Bookmark

DOP001Extraintestinal manifestations in participants with moderately to severely active Crohn’s disease: Results from the phase 3 GALAXI 2 & 3 studies

Key Points

Discussion

Implication

Cite This Study

DOP001Extraintestinal manifestations in participants with moderately to severely active Crohn’s disease: Results from the phase 3 GALAXI 2 & 3 studies

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider